Reuters logo
BRIEF-OncoTherapy Science says business and capital alliance with Theragen Etex
July 12, 2017 / 5:44 AM / 4 months ago

BRIEF-OncoTherapy Science says business and capital alliance with Theragen Etex

July 12 (Reuters) - OncoTherapy Science Inc

* Says it will establish a wholly owened subsidary on July 24

* Say it will transfer research and development of cancer immunotherapy related business to the subsidiary, effective Nov. 1

* The subsidary will issue 150 new shares to Theragen Etex Co., Ltd., at the price of 1 million yen per share, or 150 million yen in total, and payment date on Aug. 7

* Theragen Etex Co., Ltd. will acquire 310 shares of the subsidiary, at the price of 1 million yen, for 310 million yen in total, from the co, effective Nov. 15

* Say the co and Theragen Etex Co., Ltd. Will hold a 64 percent stake and a 36 percent stake finally

Source text in Japanese:goo.gl/W6DAhV

Further company coverage: (Beijing Headline News)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below